Funding for this research was provided by:
H.Lundbeck A/S and Otsuka
Received: 7 April 2017
Accepted: 30 January 2018
First Online: 5 February 2018
Ethics approval and consent to participate
: The study was conducted in compliance with relevant codes of conduct from the European Pharmaceutical Market Research Association and the Insights Association (formerly known as CASRO). As a market research study, Clinical Research Ethics Committee or Independent Review Board approval was not required. Respondents were recruited using consumer panels where all panelists have provided written consent to participate in research.
: Not applicable.
: RM reports that in the previous 12 months, he received research grants from Alkermes, Allergan, Genomind, Takeda. He has been a consultant for GuidePoint Global, Lundbeck, Neurocrine, and Otsuka. He has developed and delivered educational activities for PsychU, funded by Otsuka Pharmaceuticals. He receives book royalties from On Demand Publishing and Kindle Direct Publishing. AF reports that he is /has been a consultant and/or a speaker and/or has received research grants from Allergen, Angelini, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Eli Lilly, Ferrer, Janssen, Lundbeck, Novartis, Otsuka, and Roche. EW was employed by H.Lundbeck A/S at the time of the study and CW is employed by Otsuka.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.